NCT06951464 2025-07-23
A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
Sichuan University
Phase 2 Recruiting
Clinical Trials
17 trialsNCT06752408 2024-12-30
ANOTHER
Peking Union Medical College Hospital
Phase 2 Not yet recruiting
NCT04685070 2024-08-14
Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Active not recruiting
NCT06463171 2024-06-17
Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT06452433 2024-06-11
Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT06300424 2024-04-17
NEOVADE
Guangdong Provincial People's Hospital
Phase 2 Recruiting
NCT05946460 2024-02-06
Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.
The First Affiliated Hospital of Guangzhou Medical University
Phase 2 Unknown
NCT06185400 2023-12-29
RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT04922138 2023-04-21
APPOINT
Shanghai Chest Hospital
Phase 2 Unknown
NCT04519983 2023-03-20
Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs
Shanghai Cancer Hospital, China
Phase 2 Unknown
NCT04755738 2021-09-05
MWA
Qianfoshan Hospital
Phase 2 Unknown
NCT04978753 2021-07-27
the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT04952168 2021-07-07
Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
Tongji Hospital
Phase 2 Unknown
NCT04905550 2021-06-02
Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC
Chongqing University Cancer Hospital
Phase 2 Unknown
NCT04882345 2021-05-11
ACTIVE
Shanghai Chest Hospital
Phase 2 Unknown
NCT04636593 2021-01-12
A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC
First People's Hospital of Hangzhou
Phase 2 Unknown
NCT04455594 2020-07-02
ANSWER
The First Affiliated Hospital of Guangzhou Medical University
Phase 2 Unknown